853297-17-3

Basic information

• Product Name: 4-(4-Cbz-piperazin-1-yl-methyl)-2-trifluoromethylaniline
• Synonyms: 4-(4-Cbz-piperazin-1-yl-methyl)-2-trifluoromethylaniline
• CAS NO: 853297-17-3
• Molecular Formula: C₂₀H₂₂F₃N₃O₂
• Molecular Weight: 393.4
• Mol File: 853297-17-3.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(4-Cbz-piperazin-1-yl-methyl)-2-trifluoromethylaniline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-Cbz-piperazin-1-yl-methyl)-2-trifluoromethylaniline(853297-17-3)
• EPA Substance Registry System: 4-(4-Cbz-piperazin-1-yl-methyl)-2-trifluoromethylaniline(853297-17-3)

Safety Data

• Hazardous Substances Data: 853297-17-3(Hazardous Substances Data)

Usage

Description

4-(4-Cbz-piperazin-1-yl-methyl)-2-trifluoromethylaniline is a chemical compound that belongs to the family of aniline derivatives. It is composed of a piperazine ring substituted by a trifluoromethylphenyl group and a Cbz (carboxybenzyl) group. This unique structure makes it a valuable tool for drug discovery and development, with potential applications in the pharmaceutical industry.

Uses

Used in Pharmaceutical Industry:
4-(4-Cbz-piperazin-1-yl-methyl)-2-trifluoromethylaniline is used as a key intermediate in the synthesis of various pharmaceuticals, including antipsychotic and antihistamine drugs. Its unique structure allows for the development of potential therapeutic agents for various diseases and disorders.
Used in Drug Discovery and Development:
4-(4-Cbz-piperazin-1-yl-methyl)-2-trifluoromethylaniline is utilized in medicinal chemistry for the design and synthesis of new drug candidates. Its versatile chemical properties enable the exploration of novel therapeutic approaches and the advancement of drug development in the pharmaceutical industry.

Upstream product

• 853297-16-2 4-[4-(2,2,2-trifluoro-acetylamino)-2-trifluoromethyl-benzyl]-piperazine-1-carboxylic acid benzyl ester 

Relevant articles and documents

DIARYL UREA DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES

The invention relates to the use of diaryl urea derivatives for the manufacture of pharmaceutical compositions for the treatment of RET dependent disorders, especially RET dependent tumor diseases. The invention further relates to novel N-[4-(pyrimidin-4-yloxy)-phenyl]-N’-phenyl-urea derivatives and their use in the treatment of the animal or human body, especially in the treatment of a protein kinase dependent disease, to pharmaceutical compositions comprising such novel N-[4-pyrimidin-4-yloxy)-phenyl]-N’-phenyl-urea derivatives and to the use of such novel N-[4-(pyrimidin-4-yloxy)-phenyl]-N’-phenyl-urea derivatives for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as tumour diseases.